康辰药业(603590.SH)发预增，预计2025年度归母净利润1.45亿元到1.75亿元，同比增加243%到315%

Core Viewpoint - Kangchen Pharmaceutical (603590.SH) expects to achieve a net profit attributable to shareholders of the parent company between 145 million to 175 million yuan for the year 2025, representing a year-on-year increase of 243% to 315% [1] Financial Performance - The company reported that the previous year's financial results were negatively impacted by goodwill impairment losses due to the acquisition of the original Tai Ling Pharmaceutical International Co., Ltd. (now renamed Fangheng Pharmaceutical International Co., Ltd.) [1] - There will be no impact from goodwill impairment provisions in the current reporting period [1]